摘要
目的研究对免疫复合物型治疗性乙型肝炎疫苗不同应答的乙型肝炎患者的乙型肝炎病毒(HBV)基因型有无差别。方法收集67例经60μg乙型肝炎表面抗原-抗体(HBsAg-HBIG,YIC)治疗的慢性乙型肝炎患者血清,用S基因聚合酶链反应-限制性片段长度多态性分析(PCR-RFLP)法对其进行HBV基因分型,并结合患者对YIC治疗的不同应答进行分析。结果67例感染(HBV)患者中,HBVB基因型22例,C基因型43例,未确定者2例。感染HBVB、C两种基因型的患者对YIC免疫治疗的病毒学与HBeAg的血清转换应答差异无统计学意义。结论HBVB或C基因型不影响慢性乙型肝炎患者对YIC的治疗应答。
Objective To study whether there are differences in the response of chronic hepatitis B patients infected with different hepatitis B virus （HBV） genotypes to an HBsAg-HBIG therapeutic vaccine.Methods Serum samples from 67 chronic hepatitis B patients who completed the full course of immunization with 60 μg HBsAg-HBIG （YIC） were examined for the presence of their specific virus genotypes by PCR-RFLP, in association with their viral and HBeAg sero-conversion responses to YIC treatment.Results Among the 67 patients, 22 were infected with HBV genotype B, and 43 were infected with genotype C, while the HBV genotype could not be identified in 2 patients. In association with the responses to YIC treatment, no significant therapeutic differences were found between patients who were infected with HBV genotype B or with HBV genotype C. Conclusion Infections with HBV genotypes B or C do not differ in response to YIC in chronic hepatitis B patients.
出处
《微生物与感染》
2008年第1期7-10,共4页
Journal of Microbes and Infections
基金
国家"863"高科技项目2002AA2Z3303
